Replies to post #26884 on Amarin Corp Plc (AMRN)

[Biobillionair]

Is this the excuse for the FDA f'n up......?



1) many studies of add-on combination therapy versus the same statin dose or nonstatin monotherapy were excluded because they did not address the Key Questions

2) Given several previous reviews on dietary modification and reduction of lipids and CVD risk, we did not include these therapies in this

3) Further, we did not examine differences in statin response based on genetic variations

4) we excluded non–English-language publications, although we do not believe this introduced significant bias.

5) Third, because this review was conducted prior to the release of the 2013 cholesterol treatment guidelines from the American College of Cardiology/American Heart Association Task

6) we could not define our population eligibility criteria to match their four “statin benefit groups” and our potency categorizations differ slightly from those in the guidelines.



//////Notice how they lost track of how many excuses they have////// It's truly frightening that these people are in charge of keeping us safe!!!


"The review process imposed limitations as well. First, the review focused narrowly on combination therapy compared with statin intensification. As a result, many studies of add-on combination therapy versus the same statin dose or nonstatin monotherapy were excluded because they did not address the Key Questions. Given several previous reviews on dietary modification and reduction of lipids and CVD risk, we did not include these therapies in this review.18,19 Further, we did not examine differences in statin response based on genetic variations.20,21 Second, we excluded non–English-language publications, although we do not believe this introduced significant bias. Third, because this review was conducted prior to the release of the 2013 cholesterol treatment guidelines from the American College of Cardiology/American Heart Association Task Force, we could not define our population eligibility criteria to match their four “statin benefit groups” and our potency categorizations differ slightly from those in the guidelines."

[sts66]

Combination Therapy With Omega-3 Fatty Acid and Statin Compared to Intensification of Statin Monotherapy

No trials were identified that compared a combination of Omega-3 fatty acid with statin to intensification of statin monotherapy; therefore, the strength of evidence is insufficient for all outcomes.

Once again, American researchers refuse to believe Japanese are part of the human race! No mention of JELIS? Great meta-search, guys.